Cephalexin
NDC Package 82982-024-20

11-digit billing NDC: 82982002420

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Cephalexin is 1.1 Respiratory Tract InfectionsCephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae and Streptococcus pyogenes.1.2 Otitis MediaCephalexin is indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis.1.3 Skin and Skin Structure InfectionsCephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes.1.4 Bone InfectionsCephalexin is indicated for the treatment of bone infections caused by susceptible isolates of Staphylococcus aureus and Proteus mirabilis.1.5 Genitourinary Tract InfectionsCephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.1.6 UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, Cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Marketed by Pharmasource Meds, Llc, this product is identified by NDC 82982-024 and is authorized under FDA application ANDA090836.

Identification & Billing

NDC Package Code
82982-024-20
Package Description
20 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
82982002420

Clinical Specifications

Proprietary Name
Cephalexin
Dosage Form
-
Usage Information
1.1 Respiratory Tract InfectionsCephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae and Streptococcus pyogenes.1.2 Otitis MediaCephalexin is indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis.1.3 Skin and Skin Structure InfectionsCephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes.1.4 Bone InfectionsCephalexin is indicated for the treatment of bone infections caused by susceptible isolates of Staphylococcus aureus and Proteus mirabilis.1.5 Genitourinary Tract InfectionsCephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.1.6 UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, Cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Pharmasource Meds, Llc
FDA Application #
ANDA090836
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-09-2023
End Marketing Date
07-31-2026
Listing Expiration
07-31-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82982-024-20 identifies a specific commercial package of 20 capsule in 1 bottle of Cephalexin, labeled by Pharmasource Meds, Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Pharmasource Meds, Llc on January 09, 2023. The current certification is valid through July 31, 2026.

How is this Pharmasource Meds, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82982002420. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
82982-024-20
11-Digit CMS (5-4-2)
82982-0024-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.